trulicity solution for injection
eli lilly and company - dulaglutide - solution for injection - 1,5mg/0.5ml
victoza solution for s/c injection
novo nordisk a/s - liraglutide - solution for s/c injection - 6mg/ml
bydureon polvo y disolvente para suspensión inyectable de liberación prolongada en pluma prellenada.
astrazeneca camcar, s.a. - exenatide - exenatide....2,00 mg
byetta 5 ug injection
astrazeneca pharmaceuticals (pty) ltd - injection - see ingredients - each dose contains exenatide 5,0 ug
byetta 10 ug injection
astrazeneca pharmaceuticals (pty) ltd - injection - see ingredients - each dose contains exenatide 10,0 ug
bydureon bcise injection
astrazeneca pharmaceuticals (pty) ltd - injection - 2,0 mg - each dose (0,85 ml) contains exenatide 2,0 mg
saxenda
novo nordisk pharmaceuticals ltd - liraglutide 6 mg/ml; - solution for injection - 6 mg/ml - active: liraglutide 6 mg/ml excipient: dibasic sodium phosphate dihydrate hydrochloric acid phenol propylene glycol sodium hydroxide water for injection - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of · 30 kg/m2 or greater (obese) or · 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea. treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.
trulicity 0.75mg solution for injection in pre-filled pen
zuellig pharma sdn bhd - dulaglutide -
saxenda 6mgml solution for injection in pre-filled pen
novo nordisk pharma (malaysia) sdn. bhd. - liraglutide -
soliqua solostar 100unitsml+33mcgml solution for injection in a pre-filled pen
sanofi-aventis (malaysia) sdn. bhd. - insulin glargine; lixisenatide -